Alexandria Hammond
Stock Analyst at Wolfe Research
(1.04)
# 3,576
Out of 4,734 analysts
13
Total ratings
33.33%
Success rate
-7.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $687.80 | +67.20% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $26.64 | -6.16% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $35.89 | +11.45% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $96.24 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly | Initiates: Outperform | $1,000 | $742.35 | +34.71% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $148.15 | +28.25% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $92.96 | +18.33% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $57.04 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $140.98 | - | 1 | Nov 15, 2024 | |
| ABBV AbbVie | Initiates: Outperform | $205 | $172.61 | +18.76% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $30 | $25.60 | +17.19% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $307.08 | -51.15% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $6.58 | +355.93% | 1 | Apr 22, 2024 |
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $687.80
Upside: +67.20%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $26.64
Upside: -6.16%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $35.89
Upside: +11.45%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $96.24
Upside: -
Eli Lilly
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $742.35
Upside: +34.71%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $148.15
Upside: +28.25%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $92.96
Upside: +18.33%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $57.04
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $140.98
Upside: -
AbbVie
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $172.61
Upside: +18.76%
Apr 22, 2024
Reinstates: Neutral
Price Target: $30
Current: $25.60
Upside: +17.19%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $307.08
Upside: -51.15%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $6.58
Upside: +355.93%